Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What is causing the bounce and volume? I don’t see any news.
$BTCY: This bad boy is a buy here at $3 now ✨ @biotricity_inc is improving lives through innovation in remote patient monitoring. $BTCY is a medical technology company committed to improving healthcare by developing solutions that aid chronic disease prevention and management. pic.twitter.com/f9Tytzxt59
You will easily see this over $20 next year.
I guarantee IT !!!!!!!!!!
Uplist from OTC to Nasdaq today is just the beginning.
Watch and see them strike some Pretty MAJOR deals soon enough
GO $BTCY
Benzinga BTCY presentation:
The business model and structure of this company is spot on.
Their conference call on Aug 16 explains both of these.
7:47a ET 9/15/2021 - Benzinga
Biotricity Continues to Transform the Way We Do Health: Medtech Launches New Biokit Solution, Aims at Personal Health Monitoring
Mentioned: BTCY DOCS TDOC
Biotricity (NASDAQ: BTCY) is reforming the healthcare market as one of the fastest-growing companies in medtech. The company bridges the gap in remote cardiac monitoring, preventive and chronic care management by using the power of IoT (internet of things), wearables, and connected devices.
Not only does the company offer real-time, comprehensive monitoring and diagnostic services for cardiac-related healthcare and comorbidities, but its devices are also built with features that can dispatch emergency care services should any anomalies or arrhythmias occur when a device is worn.
Continuing Innovation in Medtech
Biotricity strikes again, unveiling its new user-centric Biokit, September 14, 2021.
Launching a suite of 3 new personal medical devices, the company prepares to expand its cardiac disease management capabilities by adding these innovative new tools to the Biotricity ecosystem.
Unlike the doctor-prescribed Bioflux device, the Biokit is a bundled series of tools and management devices that's been designed for home-use and is comprised of:
A digital thermometer
A pulse oximeter
A blood pressure cuff
All three devices are FDA-cleared, wireless compatible and easily integrated into the Biotricity ecosystem, a platform developed for the seamless interconnectivity of monitoring devices and data management platforms. The Biokit itself was developed to address the challenges that exist with currently offered home-based medical devices.
According to its recent announcement, this is the next step in the evolution of the Bioflux solution, where other available tools are fully integrated and will, together, act as a complete solution for at-home remote cardiac monitoring.
'Biokit is a natural extension of our Bioflux heart-monitor, cardiac-diagnostic offering. For patients with cardiac disease, a personal medical device kit is ideal for long-term monitoring,' stated Dr. Waqaas Al-Siddiq, CEO and founder of BioTricity. 'After speaking with both patients and physicians, it was clear that a product like this was an immediate need.'
The kit is currently in its final stage of production, and the company expects the new personal devices to hit consumer markets by early 2022.
The Biokit will also expand the company's total addressable market, which now includes over 2.2 million customers served at more than 1,000 doctors offices per year. In fact, it is likely that the Biokit will actually surpass Bioflux within the healthcare market, as it reaches customers at home well before a Bioflux has actually been prescribed.
The combination of the Bioflux and Biokit is possibly poised to break records for innovation within the healthtech and medtech markets. Biotricity will soon offer a comprehensive cardiac diagnostics product line for effective, accurate and economic long-term disease management, in addition to personal home monitoring and remote cardiac monitoring for post-diagnostic care.
'We created the Biokit to strengthen our long-term vision of supporting diagnosed cardiac patients throughout their cardiac health journey,' Al-Siddiq explained. 'I am pleased with how quickly we have been able to develop a solution to fulfill this customer feedback, which is a testament to the team here.'
Devices within the Biokit are able to directly integrate with other tools and platforms within the Biotricity ecosystem and include the following:
Biokit BP: A wireless digital blood pressure cuff, enabling blood pressure data collection
Biokit TP: A wireless digital thermometer, allowing patients to collect temperature data
Biokit 02: A wireless digital pulse oximeter, facilitating the collection of blood-oxygen data
These tools enable patients to track and store their data within HIPPA-compliant data management solutions. Most importantly, this data is also stored and available for interim review by physicians prior to diagnosis and during preventative follow-up visits.
Why You Should Be Paying Attention
The company has shown triple-digit, quarter-over-quarter, year-over-year growth since its inception. This growth has led Biotricity to be self-sufficient and innovative as it grows. With an existing customer base, a well-respected footprint within the medical community and a high rate of retention, Biotricity might be well-positioned to dominate this space for years to come.
Some people consider Biotricity to be a 'mash-up' of Doximity (NYSE: DOCS), Livongo (NASDAQ: LVGO) and Teladoc (NYSE: TDOC), but with a focus on cardiac disease and monitoring, the number one killer and one of the biggest healthcare markets..
To learn more about Biotricity's suite of remote cardiac monitoring tools, please visit https://www.biotricity.com. To find out more about Dr. Waqaas Al-Siddiqand why his wearables could be among the most crucial devices ever seen, be sure to check out this recent article by Benzinga.
The author of this article owns shares in one or more of the stocks mentioned.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
REDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today reported its CEO Waqaas Al-Siddiq is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be available on-demand starting at 7:00 a.m. ET on Monday, September 13, 2021 (details provided below).
Dr. Al-Siddiq will discuss the Company's continuing sales growth of its FDA-approved Bioflux® mobile cardiac telemetry (MCT) device which, as the Company previously announced, drove its FY22-1Q revenue up 290% YOY and approximately 49% sequentially. He will also discuss sales expansion and the company's planned product portfolio that the Company believes will increase the current total addressable market (TAM) while growing revenues. As previously announced, Biotricity recently completed a $15 million equity raise and listed on the Nasdaq Capital Market.
The presentation will be available to registered attendees from Monday, September 13 to Wednesday, September 15.
BTCY moved to the Nasdaq from the OTC:
https://otce.finra.org/otce/dailyList?viewType=Deletions
I agree . More buys than sales today and prices drops , must be taking out all and any stop losses
Earnings is out, check out the release. Some of the positive highlights:
* Q4 revenue of $1.2M (up from $1.0M last quarter)
* Quarterly revenue increased 227% (162% increase posted in prior quarter)
* Annual revenue of $3.4M (increase of 139% over fiscal 2020)
* Gross operating expenses grew at slower pace than revenue in Q4
Looking good. Waiting for that up list to the exchange.
$3.25 close yesterday on strong volume. Must be due to the presentation at LD Micro. This company is making great progress, delivering results, and the share price is reflecting that. Hit $3.75 already today, a new 52 week high. Earnings coming up on June 15th.
Great writeup on BTCY on Seeking Alpha: thoughtful, logical, and realistic assessment of the upside potential here. This is not hype, this is a company that is executing on its plan, and delivering results. See here: https://seekingalpha.com/article/4429296-biotricity-stock-can-triple-within-18-24-months
Further confirmation of the growth BTCY has experienced, and will be experiencing going forward. Run rate of over $7M/year in revenues, not taking into consideration any future sales/growth.
https://www.biotricity.com/biotricity-to-report-record-revenue-results-for-fiscal-2021/
Further confirmation of the growth BTCY has experienced, and will be experiencing going forward. Run rate of over $7M/year in revenues, not taking into consideration any future sales/growth.
https://www.biotricity.com/biotricity-to-report-record-revenue-results-for-fiscal-2021/
Further confirmation of the growth BTCY has experienced, and will be experiencing going forward. Run rate of over $7M/year in revenues, not taking into consideration any future sales/growth.
https://www.biotricity.com/biotricity-to-report-record-revenue-results-for-fiscal-2021/
AUSTIN, Texas, March 16, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Waqaas Al-Siddiq, CEO of Biotricity Inc. (OTCQB: BTCY) (“the Company”), a modern medical technology company delivering disruptive solutions to the multi-billion-dollar cardiac monitoring and diagnostic market.
Biotricity’s flagship Bioflux® product is a wearable medical device that enables physicians to accurately monitor and diagnose cardiac patients in real-time for effective treatment and pain management. While this technology alone targets a massive demographic, the Company’s full pipeline of remote cardiac monitoring and diagnostic solutions provides access to a multi-billion-dollar market hungry for digital innovation.
Speaking with SCV’s Stuart Smith, Dr. Al-Siddiq describes how Biotricity builds and delivers its technology to benefit patients, care providers and the broader healthcare industry, while building long-term value for the Company.
“What we’ve noticed primarily across healthcare, is that technology is owned by clinical players – players that are actually performing the diagnostic tests,” he says. “Our model is very different. We want to enable physicians, hospitals and organizations to do that work so we can stay focused on things of a technology company.”
Biotricity’s monitoring devices are built in-house and are reusable, which saves on costs and enables exponential revenue growth through a recurring technology fee and greater market reach.
“That’s where we have been really fortunate to have a cycle of growth over growth,” explains Dr. Al-Siddiq. “We have a sales force, and the idea is for us to continue to open up more clinics, more hospitals, and get our devices into more hands.”
Biotricity currently has a sales presence in 20 U.S. states. Near-term growth plans include launching more products from the Company’s pipeline and expanding its sales force to target a larger addressable market.
“The most successful medical device and pharma companies have a direct sales force in their key markets and then they have distribution elsewhere,” says Dr. Al-Siddiq. “We are following the exact same track.”
Dr. Al-Siddiq also highlights the experience of Biotricity’s staff and how it was able to leverage that expertise to stride through the challenges of the pandemic and meet demand for remote monitoring.
“Intelligent monitoring and the value of it became very, very clear because of the pandemic,” he says. “The awareness and the need for it increased. The ability to sell was of course limited, but despite that, we were able to grow … Once this pandemic is more under control, I think it’s going to actually crate a boost in our growth in the long term.”
As the Company ramps up its sales force, it is also focused on the release of a new product and uplisting to a national exchange for greater visibility. Of significance, says Dr. Al-Siddiq, is for investors to remember Biotricity’s application to the healthcare industry and how that affects revenues.
“We are a technology company, not a clinical company,” he tells Smith. “Our focus is providing technology to physicians and healthcare companies in a business model that is anchored in reimbursement and a reoccurring revenue model. That is something that creates and accelerated growth and gives us a very high value long term. Being a technology player with a reoccurring business model places us at the top of the food chain when it comes to how to value the company. And we’ve done that in a very specific and concerted way.”
The full interview can be heard at: https://www.smallcapvoice.com/interview-biotricity-btcy/.
Biocare Telemed is a virtual clinic platform with secure HIPPA compliant technology.
The platform enables clinicians to provide outstanding patient care remotely, ensuring at-risk patients and those needing remote cardiac monitoring do not have to leave the safety of their home. The user-friendly platform ensures seamless integration in to the clinics’ current workflow, saving time and reducing costs.
For the patients this means:
Convenient appointment booking
Access when and where needed
Avoid time-off work
Skip the waiting room
Avoid catching an illness
Reduce the anxiety
Bioflux® is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of your ambulatory patients’ ECG information. The Bioflux® system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians’ existing platforms and workflows.
We track over 100 billion heartbeats a year, monitored in real-time by our certified cardiac technicians with unmatched reporting capabilities.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and ?lifestyle improvement
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA), on December 31 2020, for Biotres. The company expects this process to take at least 4 months, and if the Company’s 510(k) application is cleared by the FDA the Company expects a product launch thereafter.
As announced previously, Biotres is a 3-lead patch product for ECG and arrhythmia monitoring for patients at risk for or being diagnosed with certain cardiac issues. Biotres can work as a Holter, Event Loop, and Extended Holter.
“We are excited to announce the 510(k) FDA submission for Biotres and look forward to building out our product offerings further in 2021,” stated Waqaas Al Siddiq, CEO of Biotricity. “We believe that Biotres addresses demand from some of our existing customers and a need in the holter market.”
The Biotres is a holter product that was developed to address the challenges that exist with current holter patch products. The Biotres is designed with the following key features:
3 Channel Recording – A wearable holter patch device that can provide continuous 3 channel recording of ECG (heart) data. All other holter patch devices are 1 channel or 2 channels.
Rechargeable Battery – The device can be worn continuously for 48 hours, before needing to be charged for 1 hr., enabling continuous data collection for extended periods of time without any intervention, something not possible with traditional holter patch solutions.
Wireless Connectivity – The unique device utilizes Bluetooth technology to offload data, reducing the time for diagnoses. Current holter patch solutions can take up to a week before diagnoses are available due to manual data downloading and a lack of connectivity.
User-Friendly Design – Easy to understand and comfortable to wear during regular day-to-day activities.
ELLIOTT WAVE counts
Another nice up day, trading at $3.19 currently (10%+ gain today)...how many people know about this company? Seems like more are becoming aware, but generating a LOT more interest is going to trigger a lot more buying activity and upside.
Long here fellas
I agree. Discovered this company a couple years ago and have just been adding shares on price dips since then. Their patient, doctor, company relationship makes a lot of sense with the Biotres product and then they have two more products in the pipeline to be released later this year.
Surprised there is no activity lately. I've owned this stock since late 2017, have held my shares, and added more at the end of last year when it was at $.75. If you haven't checked out their recent earnings announcements/webcasts, news releases, and last week's Motley Fool writeup on them, check it out. BTCY has the potential to be a real winner, and that seems to be reflected in the recent stock share appreciation. No hype here: just a small, unknown company that is growing and executing on its business plan. Curious as to what others think? It is over $3 today, up 18%, on lots of trading activity. I'm finally in the green, but I'm not selling. Tons of upside.
Might be time for me to get back in this one.
News; $BTCY Biotricity Launches Biocare Telemed for Safe and Convenient Remote Patient Care
REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc . (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today introduced Biocare Telemed, a virtual clinic that provides user-friendly access for patients to receive outstanding medic...
Read the whole news BTCY - Biotricity Launches Biocare Telemed for Safe and Convenient Remote Patient Care
JUST IN: $BTCY Biotricity Accelerates Shift to Remote Monitoring with Bioflux® Direct Program
REDWOOD CITY, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the launch of its Bioflux® Direct Program. The new offering ships Bioflux devices directly to at-risk patients who...
Got this from BTCY - Biotricity Accelerates Shift to Remote Monitoring with Bioflux® Direct Program
Anybody have a clue what caused that 26% drop in only 10 trading days ending yesterday? We've had nothing but positive news lately. Are we a target for short sellers?
We get an FDA clearance and barely a sp move. Other medical stocks skyrocket on this kind of news. We need more eyeballs on this company. Time for a dog-and-pony show. Now we're buying a telemedicine company which is just as good news because it fits perfectly to what BTCY does. Good sp move on this news.
News: $BTCY Biotricity Signs Agreement with Telemedicine Company
REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, today announced that it has entered into an Agreement that establishes terms under which Biotricty will enter into a licensing ag...
In case you are interested BTCY - Biotricity Signs Agreement with Telemedicine Company
FDA clearance for Bioflux Software II System
https://www.otcmarkets.com/stock/BTCY/news/Biotricity-Receives-FDA-clearance-for-Bioflux-Software-II-System?id=269603
5G First Responder Lab:
A Commitment to Public Safety.
The future of public safety technology will be powered by 5G networks. From critical communications, to situational awareness, to virtual reality, to drones; 5G will enable life saving capabilities that will empower the first responders who protect our communities. Verizon and ResponderXLabs are committed to delivering those vital capabilities as soon as possible. 5G First Responder Lab will help deliver that commitment by working alongside boots-on-the-ground to identify the most pressing needs, and the global entrepreneurial community to source the leading solutions. In 2019, 5G First Responder Lab will enable 15 emerging technologies with the power of 5G, and then we’ll deliver those solutions to public safety agencies throughout the country. No whitepapers, no hackathons. Real solutions, real deployments. 5G First Responder Lab will do more than just enable technology; we’ll make sure that technology is what first responders truly need, and we’ll make sure it’s available for every agency. That’s our commitment to public safety.
Program Benefits:
5G Enablement
Agency Sales Acceleration
Showcase Opportunities
Press & Demo Exposure
Pilot Opportunities
Potential Venture Investment
Potential Product Distribution
Biotricity(R) Partners with Verizon to Develop EMS Solutions
8:00 AM ET 7/14/20 | Dow Jones
Related Quotes
10:05 AM ET 7/14/20
Symbol Last % Chg
BTCY
1.59 4.61%
Real time quote.
Biotricity(R) Partners with Verizon to Develop EMS Solutions
Verizon to Integrate the Bioflux(R) Solution into their EMS and Launch to Existing and Future Customers
REDWOOD CITY, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company announced a strategic partnership with Verizon (NYSE: VZ) to develop EMS solutions for First Responders by integrating its Bioflux solution. Bioflux is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of patients' ECG information. Integrating the Bioflux solution into Verizon's EMS platform realizes an unmet need for First Responders, enabling them to access critical, potentially life-saving data in real-time and respond immediately in a crisis.
"We at Biotricity are committed to developing innovative technology that provides healthcare workers and medical professionals the vital patient data they need. Collaboration with Verizon offers an exciting avenue for our team of experts to deliver frontline workers a device that provides remote patient diagnostics in real-time and potentially saves lives," said Spencer LaDow, VP of Research & Development.
First Responders require connectivity and specialized equipment to enable immediate response in a crisis. Biotricity's device provides continuous connectivity, real-time monitoring and diagnostic reporting that will be integrated into Verizon's current EMS platform, fulfilling an unmet need. Partnering with Verizon allows the company to fill this gap and access a new market while adding a revenue stream. Once integrated, Verizon will use its ecosystem and resources to bring the solution to market.
"Our technology is an obvious fit for a variety of markets, and it is a privilege to see it applied in vital health care areas such as First Responders. As a growing company, we have focused on the remote patient monitoring market but are aware of the potential in other markets for our solutions. Partnerships like this enable us to expand our opportunities, creating new revenue streams, while focusing on our core market," said Dr. Al-Siddiq, CEO of Biotricity.
To learn more about this partnership, read Verizon's Press Release here.
Join our newsletter at: https://www.biotricity.com/contact-us/ or follow on:
Twitter: @biotricity_inc
Facebook: facebook.com/biotricity/ or
LinkedIn: linkedin.com/company/biotricity-measuring-vitals
Verizon accelerates 5G-enabled EMS solutions with new cohort of its 5G First Responder Lab
Media contact(s)
Chris Ashraf
908-381-2384
christina.moon.ashraf@verizon.com
Najuma Thorpe
732.427.2304
najuma.thorpe@verizon.com
What you need to know:
Companies in fourth cohort will focus on 5G-enabled solutions to common challenges along the typical EMS/patient journey
5G’s fast speed, massive bandwidth and low latency could aid autonomous dispatch, tracking and monitoring and more
Applications now being considered for fifth cohort focusing on fire response and situational awareness
""
NEW YORK – As part of Verizon’s continued commitment to invest in public safety and support first responders, the company has chosen five companies to take part in the fourth cohort of its 5G First Responder Lab. The companies will work together to accelerate 5G development of solutions to common challenges along the EMS/patient journey from pre-incident and emergency response to treatment and recovery, all powered by Verizon’s 5G Ultra Wideband network.
“With the COVID-19 global pandemic, EMS workers on the frontlines are struggling with a heavy workload and oftentimes a lack of vital information at their fingertips,” said Andrés Irlando, senior vice president and president, Public Sector and Verizon Connect at Verizon. “Solutions built on Verizon’s 5G Ultra Wideband network will put critical information in the hands of EMS workers by enabling innovations like smart dispatching, non-emergent interventions, telehealth and remote diagnostics. We’re excited to see the potentially life-saving solutions developed by these innovators when given access to Verizon’s 5G Ultra Wideband network.”
The companies participating in this cohort include:
Biotricity: Focuses on near real-time remote medical monitoring
Rave Mobile Safety: Offers a critical communications and data sharing platform
DispatchHealth: Provides on-call medical care to your door
Vuzix: Uses augmented reality to better inform First Responders
Visionable: Provides a platform for near real-time medical collaboration
Over the next six months, these companies will have access to Verizon 5G specialists, engineers and Verizon’s 5G Ultra Wideband network to further develop their solutions using 5G’s high speed and ultra-low latency capabilities. The 5G First Responder Lab launched in November 2018 in partnership with Responder Corp. as a first-of-its-kind innovation program to identify promising technology companies, and give them access to 5G technology to test and refine their 5G solutions for public safety. The first three cohorts included 15 startups who tested their developments on 5G Ultra Wideband, including autonomous persistent drones for security and situational awareness, gun detection software using existing municipal cameras, computer vision heads up display for firefighters to see through smoke, and VR training for police officers and EMTs. Verizon continues to explore partnership opportunities with several of these startups.
Verizon is also now accepting applicants for the fifth cohort of its 5G First Responder Lab focused on fire response and situational awareness solutions. The fifth cohort participants will be selected in Q4 2020. Apply here.
Learn more about Verizon 5G Labs and Verizon 5G technology. View previous cohorts of the First Responder Lab by clicking on the Alumni tab here.
Tags:
Verizon accelerates 5G-enabled EMS solutions with new cohort of its 5G First Responder Lab
Media contact(s)
Chris Ashraf
908-381-2384
christina.moon.ashraf@verizon.com
Najuma Thorpe
732.427.2304
najuma.thorpe@verizon.com
What you need to know:
Companies in fourth cohort will focus on 5G-enabled solutions to common challenges along the typical EMS/patient journey
5G’s fast speed, massive bandwidth and low latency could aid autonomous dispatch, tracking and monitoring and more
Applications now being considered for fifth cohort focusing on fire response and situational awareness
""
NEW YORK – As part of Verizon’s continued commitment to invest in public safety and support first responders, the company has chosen five companies to take part in the fourth cohort of its 5G First Responder Lab. The companies will work together to accelerate 5G development of solutions to common challenges along the EMS/patient journey from pre-incident and emergency response to treatment and recovery, all powered by Verizon’s 5G Ultra Wideband network.
“With the COVID-19 global pandemic, EMS workers on the frontlines are struggling with a heavy workload and oftentimes a lack of vital information at their fingertips,” said Andrés Irlando, senior vice president and president, Public Sector and Verizon Connect at Verizon. “Solutions built on Verizon’s 5G Ultra Wideband network will put critical information in the hands of EMS workers by enabling innovations like smart dispatching, non-emergent interventions, telehealth and remote diagnostics. We’re excited to see the potentially life-saving solutions developed by these innovators when given access to Verizon’s 5G Ultra Wideband network.”
The companies participating in this cohort include:
Biotricity: Focuses on near real-time remote medical monitoring
Rave Mobile Safety: Offers a critical communications and data sharing platform
DispatchHealth: Provides on-call medical care to your door
Vuzix: Uses augmented reality to better inform First Responders
Visionable: Provides a platform for near real-time medical collaboration
Over the next six months, these companies will have access to Verizon 5G specialists, engineers and Verizon’s 5G Ultra Wideband network to further develop their solutions using 5G’s high speed and ultra-low latency capabilities. The 5G First Responder Lab launched in November 2018 in partnership with Responder Corp. as a first-of-its-kind innovation program to identify promising technology companies, and give them access to 5G technology to test and refine their 5G solutions for public safety. The first three cohorts included 15 startups who tested their developments on 5G Ultra Wideband, including autonomous persistent drones for security and situational awareness, gun detection software using existing municipal cameras, computer vision heads up display for firefighters to see through smoke, and VR training for police officers and EMTs. Verizon continues to explore partnership opportunities with several of these startups.
Verizon is also now accepting applicants for the fifth cohort of its 5G First Responder Lab focused on fire response and situational awareness solutions. The fifth cohort participants will be selected in Q4 2020. Apply here.
Learn more about Verizon 5G Labs and Verizon 5G technology. View previous cohorts of the First Responder Lab by clicking on the Alumni tab here.
Tags:
News: $BTCY Biotricity Shows Continued Growth through its Preliminary Year-End Guidance and Provides Calendar Second Quarter Update
REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. ( OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, today provided guidance on its financial results for the year ended March 31, 2020, announcing that it has experienced increa...
Got this from BTCY - Biotricity Shows Continued Growth through its Preliminary Year-End Guidance and Provides Calendar Second Quarter Update
Agreed. Can't wait!
FDA approval coming any day now !! This company is a goldmine not many people know about it yet and once they get the FDA approval this will be up 200-300%. Easily a $5 stock just on news !!
Amended Statement of Changes in Beneficial Ownership (4/a)
June 03 2020 - 04:35PM
Edgar (US Regulatory) Print
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
Al-Siddiq Waqaas 2. Issuer Name and Ticker or Trading Symbol
BIOTRICITY INC. [ BTCY ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
CEO and President
(Last) (First) (Middle)
275 SHORELINE DRIVE, SUITE 150 3. Date of Earliest Transaction (MM/DD/YYYY)
4/7/2020
(Street)
REDWOOD CITY, CA 94065
(City) (State) (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
4/9/2020
6. Individual or Joint/Group Filing (Check Applicable Line)
_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to purchase) $1.06 4/7/2020 A 1400000 (1) 4/7/2025 Common Stock 1400000 $0 1400000 D
Explanation of Responses:
(1) The options vest quarterly over four years.
Remarks:
The Amended Form 4 is being filed to correct the expiration date and exercise price.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Al-Siddiq Waqaas
275 SHORELINE DRIVE, SUITE 150
REDWOOD CITY, CA 94065 X X CEO and President
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
440
|
Created
|
06/15/16
|
Type
|
Free
|
Moderators |
Biotricity (OTCQB:BTCY) is a company most of you have never heard of, but is poised to disrupt a segment of the cardiac medical device space. Though small, it already has nearly two years of eye-popping sequential and annual growth rates. But that's just the beginning. The company has publicly guidedfor 25-40% sequential growth and continued triple digit annual growth for the next couple years, at least.
As if that growth is not impressive enough, the guidance only includes the expansion of their initial commercialized product, Bioflux, a mobile cardiac telemetry (MCT) device. Yet, in January of this year the company submitted a 510(K) FDA filing for another cardiac device, Biotres, a holter/extended holter device. This device will have a higher total addressable market (TAM) than Bioflux, and the CEO noted on the last conference call that Biotres should quickly add 20-30% more to the top line.
As mentioned, BTCY is currently focused on the cardiac market, most especially the MCT market, which is used primarily now for high-risk cardiac patients. The MCT devices and technology monitor high-risk patients in real time so that if a patient has an adverse cardiac event, such as arrythmia, the physician and patient are immediately alerted to address the problem at that time. Using a holter device, which is usually used on low to medium-risk patients, the adverse event would not be detected until the patient's next physician visit. If the patient had an adverse event while wearing the holter, the physician would not know this in real time, and the patient may have severe damage, or death, from the event not being timely-treated.
Despite the differences between an MCT and holter device and technology, the use and payment process for these devices follows the same pattern. Namely: (1) the doctor prescribes the patient to wear the device for a given period of time, e.g., seven days; (2) the patient wears the monitor for that time; (3) the doctor is paid a nominal fee for reading the device's report; (4) the medical device/clinical company is paid around $800 per use of its device; (5) if insurance does not cover all $800, the device company will likely bill the patient for the remaining balance. So, in this standard model, the doctor is paid a nominal reading fee and the patient may be billed for an amount not paid by their insurance.
BTCY's model is different. In this model, both the physician and the patient benefit. Here's BTCY's model: (1) the doctor purchases the device from BTCY; (2) the doctor prescribes the patient to wear the BTCY device for a given period of time; (3) the patient wears the monitor; (4) the doctor is not only paid the nominal reading fee, but also can bill the $800 per use of the device; (5) the doctor often chooses not to bill any difference between the $800 and the amount paid by insurance because they have a long-term relationship with the patient; (6) the doctor pays BTCY a technology fee for use of their technology in the device.
As you can see, in BTCY's model, the doctor benefits by being paid significantly more money; the patient wins by possibly being billed less, but certainly not being billed anymore; and BTCY wins not primarily through the device sale, but through the reliable, recurring, and high margin revenue from the technology fee. While BTCY sells the device once, the technology fee will repeat several dozen times per year for that one device. Notice the only ones who lose in this model: the device/clinical companies who currently cut out the physician from any meaningful payment in this process. For cardiologists and electrophysiologists who regularly prescribe MCT devices, using BTCY's product and technology (which is the most up-to-date) and billing model (which allows them to make significantly more money) seems like a no brainer. In fact, when I contacted a close friend of mine who himself is an electrophysiologist, he immediately asked me to put him in touch with the company (he lives in one of the 30 states where BTCY currently does not have a salesforce presence). Perhaps this is why BTCY is seeing eye-popping growth rates with its Bioflux device and subsequent technology fees.
While BTCY has plans to expand well beyond the adult cardiac monitoring market, I will focus on more near-term catalysts and expansion. I have already mentioned the Biotres product and technology that management indicated would quickly add 20-30% revenue increases. In addition to those, there are two other exciting developments underway.
First, is BTCY's Bioheart, a direct-to-consumer (DTC) product expected to be launched in June 2021. According to people familiar with the company, BTCY is still doing a full market assessment to see how best to market this product. In any case, Bioheart is essentially Bioflux for non-medical-professional use. I believe Bioheart could have significant appeal to people generally concerned about heart health due to family history, etc., as well as to athletes and "gym rats" who want to monitor their heart (full disclosure: I am personally quite interested in Bioheart for both of these reasons).
Second, according to its presentation from the LD Micro conference in December, the company is working on an app for cardiologists and patients to use to better monitor the patient's heart health between doctor visits. Beyond that tease, the company has not spoken publicly about the app, but they did show on that presentation that the TAM is approximately 10 times as large as the combined TAM for Bioflux and Biotres.
BTCY'S STRENGTHS
1) Gross margins: current gross margins are just a tick under 50%. While that is good, it is nothing compared to where gross margins should eventually land. The company has mentioned that margins will expand as one-time device sales become a smaller portion of revenue, giving way to the higher margin TaaS fees. Based on my own research, I would expect gross margins to easily hit the high 50% to low 60% range by the end of fiscal 2022. Long term, the company will likely eventually settle with at least mid-60% range gross margins.
(2) Churn: So far, BTCY has nearly a 100% customer retention rate. This bodes well for the company because it speaks not only to their effectiveness and good relationships with customers, but also to their visibility into future revenue run rates.
(3) The Board of Directors and management team are experienced. In addition to strong corporate and medical device commercialization experience, the team has members familiar with raising capital for new companies and taking them public. Although BTCY is obviously already public, this experience could help with this final strength I wish to mention.
(4) Uplisting to a Major Exchange: BTCY is working to be listed on a major exchange sometime in calendar year 2021. Based on my review, I believe the only necessary hurdle to being uplisted is the share price. From what I will show in the "Valuation" section, I believe that issue will take care of itself as BTCY continues to execute. But beyond that, being listed on a major exchange will provide a tailwind with analyst coverage being more likely, and additional institutional interest given that some institutions have restrictions from purchasing OTC stocks.
1) Gross margins: current gross margins are just a tick under 50%. While that is good, it is nothing compared to where gross margins should eventually land. The company has mentioned that margins will expand as one-time device sales become a smaller portion of revenue, giving way to the higher margin TaaS fees. Based on my own research, I would expect gross margins to easily hit the high 50% to low 60% range by the end of fiscal 2022. Long term, the company will likely eventually settle with at least mid-60% range gross margins.
(2) Churn: So far, BTCY has nearly a 100% customer retention rate. This bodes well for the company because it speaks not only to their effectiveness and good relationships with customers, but also to their visibility into future revenue run rates.
(3) The Board of Directors and management team are experienced. In addition to strong corporate and medical device commercialization experience, the team has members familiar with raising capital for new companies and taking them public. Although BTCY is obviously already public, this experience could help with this final strength I wish to mention.
(4) Uplisting to a Major Exchange: BTCY is working to be listed on a major exchange sometime in calendar year 2021. Based on my review, I believe the only necessary hurdle to being uplisted is the share price. From what I will show in the "Valuation" section, I believe that issue will take care of itself as BTCY continues to execute. But beyond that, being listed on a major exchange will provide a tailwind with analyst coverage being more likely, and additional institutional interest given that some institutions have restrictions from purchasing OTC stocks.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |